Lewis H Jr Titterton

Director Lewis H Jr Titterton purchases 12,000 ANIX shares at $3.47; current price $3.46; company unprofitable with $-2.5M net income.

Lewis H Jr Titterton, a Director, purchased 12,000 shares at $3.47 on 2026-07-20, increasing his holdings from 975.0K to 987.0K shares. The purchase occurred near the current market price ($3.46) and represents a modest 1.2% increase in his position. Titterton's prior trades at ANIX show mixed timing outcomes: 2 of 5 prior buys were well-timed at the 90-day mark, with two prior purchases (2025-07-31 and 2025-07-11) both posting strong 90-day gains of +35.1% and +56.7% respectively, though three earlier buys generated negative 90-day returns. The company remains unprofitable with a net income of $-2.5M and flat annual revenue growth at +0.0%, creating an environment where the timing and conviction behind insider purchases merit investor scrutiny given the lack of underlying financial momentum.

Director Titterton Lewis H jr purchases 4,761,905 shares of PRKR at $0.21, investing $1,000,000.05; holdings surge 124.8% amid -78.4% decline from 52-week high.

Titterton Lewis H jr, a director, deployed $1,000,000.05 to acquire 4,761,905 shares at $0.21, increasing his holdings from 3.82M to 8.58M shares (a 124.8% increase). The purchase occurred when the stock trades at $0.22, currently -78.4% below its 52-week high of $1.02. ParkerVision reported zero revenue in the latest quarter and a $-2.0M net loss, with annual revenue declining -100.0% year-over-year and a market cap of $26.7M. Across his full cross-ticker track record, the director's 17 prior open-market purchases averaged +2.7% return in 30 days and +13.4% in 90 days with a 76.47% 90-day win rate. The magnitude of this single transaction ($1.0M for a material block of shares) and the director's historical consistency on open-market buys present a contrasting signal against the company's operational deterioration and depressed valuation relative to recent trading history.

Director Titterton buys 10,000 ANIX shares at $3.08; holds 953.3K shares post-transaction.

Titterton Lewis H jr, a Director, purchased 10,000 shares of Anixa Biosciences at $3.08 on 2025-07-31, bringing his total holdings to 953.3K shares. This represents a modest 1.1% increase in his position. The transaction occurred at a price $0.18 below the current price of $3.26 and within the 52-week range of $2.13–$3.97. At the same-ticker level, Titterton's prior four measurable trades at ANIX delivered mixed results: only 1 of 4 prior buys showed positive 90-day returns, and his most recent purchase on 2025-07-11 remains unmeasurable. His cross-ticker track record shows stronger performance (73.33% 90-day win rate, avg 90d return +9.0%), but that does not account for his comparatively weaker performance at this specific security. The company remains unprofitable (net income $-2.8M) with stalled annual revenue growth at +0.0%, creating fundamental headwinds.

Director Titterton Lewis H jr buys 10,000 ANIX shares at $3.14 amid stalled growth and losses

Titterton Lewis H jr, a director of Anixa Biosciences, purchased 10,000 shares at $3.14 on 2025-07-11, bringing his holdings to 943,334 shares. The purchase occurred as the stock trades at $3.20, down 4.2% over 30 days and 19.4% from its 52-week high of $3.97. Fundamentally, the company reported revenue of $210,000.00 in its latest quarter with a net loss of $-2,790,000.00, and annual revenue growth stands at +0.0%, signaling a stalled business trajectory. His same-ticker history at ANIX shows mixed outcomes: 2 of 5 prior buy transactions had positive 90-day returns, but the others declined 6–10% on a 90-day basis, reflecting inconsistent timing results at this particular security.

Director Titterton Lewis H jr bought 3,000 shares at $2.94 avg (Jan 23–24); 2 other insiders also bought within 14 days; ANIX stock -43.3% from 52-week high.

Titterton Lewis H jr, a director at Anixa Biosciences, executed two separate purchases totaling 3,000 shares for $8,820.00 on January 23–24, 2025, at a blended average price of $2.94. The timing coincides with a cluster buy pattern in which 2 other insiders also purchased shares within the past 14 days. His prior trades at ANIX show a 2-of-2 well-timed pattern (both July 2024 purchases yielded positive 90-day returns of +22.3% and +29.7%), indicating consistent execution discipline at this ticker. However, the stock is currently trading at $2.78, down 43.3% from its 52-week high of $4.90, and the company reported near-zero revenue growth ($210,000 in the latest quarter) while posting a $-3.3M net loss, making it deeply unprofitable. The cluster buy activity by multiple insiders and the director's repeat accumulation despite deteriorating fundamentals merit closer scrutiny into whether recent developments have shifted the board's or management's conviction about near-term value.

Director Titterton buys 2,000 ANIX shares at $3.01; cluster buy pattern with 2 other insiders in past 14 days; 90d win rate 90.00% on prior buys

Director Lewis H Titterton Jr purchased 2,000 shares at $3.01 on 2025-01-22, expanding his holdings to 930,334 shares. This transaction is part of a cluster buy pattern, with 2 other insiders also purchasing shares within the past 14 days. Titterton's cross-ticker track record shows 13 prior buys with a 90-day win rate of 90.00% and average 90-day return of +15.2%. At ANIX specifically, his 2 prior measurable buys (2024-07-30 and 2024-07-31) both delivered positive 90-day returns: +29.7% and +22.3% respectively, indicating consistent well-timed purchases at this ticker. However, ANIX fundamentals are material headwinds: the company reported Revenue $210,000.00 in the latest quarter, negative Net income $-3,277,000.00, zero annual revenue growth, and is unprofitable, trading at -41.1% from its 52-week high despite a recent +13.2% 30-day move.

Director Titterton Lewis H jr bought 6,000 shares of ANIX at $2.59 on 2025-01-21; 2 other insiders also bought within 14 days

Titterton Lewis H jr purchased 6,000 shares at $2.59, bringing his holdings to 928,334 shares, as part of a cluster pattern with 2 other insiders buying within the past 14 days. His same-ticker history at ANIX shows 3 of 3 prior measurable buys were well-timed on the 90-day horizon (returns of +4.0%, +29.7%, and +22.3%), establishing a pattern of favorable entry timing at this company. However, the company remains unprofitable with net income of $-3.3M on quarterly revenue of $210.0K, and the stock is currently down 39.9% from its 52-week high of $4.96. The synchronized buying activity among multiple insiders warrants attention, though the company's fundamental weakness and current price position relative to 52-week range provide important context.

Director Titterton Lewis H jr bought 10,000 shares of ANIX at $2.57; all 5 prior ANIX buys were well-timed (90d wins); cluster pattern with 2 other insiders buying in past 14 days.

Titterton bought 10,000 shares at $2.57 on 2025-01-17, expanding his stake to 922,334 shares. His track record at this ticker is notably strong: all 5 prior purchases at ANIX were well-timed, with 90-day returns ranging from +4.0% to +29.7%. The current transaction arrives as the stock is down 52.0% from its 52-week high and has declined 19.9% over the past 90 days, mirroring the depressed entry points of his prior buys in late July 2024, which subsequently generated solid 90-day gains. A cluster buy—2 other insiders purchased ANIX shares within the past 14 days—reinforces this activity. Against this favorable timing pattern, the company remains unprofitable (net income of $-3.3M in the latest full fiscal year), with minimal revenue ($210.0K in the latest quarter) and zero annual revenue growth, posing fundamental risks regardless of near-term price recoveries.

Director Titterton Lewis H jr purchased 27,226 shares in ANIX for $84,260.16 at blended $3.09 average

Director Titterton Lewis H jr made two separate purchases totaling 27,226 shares for $84,260.16 ($84.3K) on July 30–31, 2024, at a blended average price of $3.09—below the current market price of $3.39. His holdings increased 3.1% from the transaction. However, his cross-ticker track record shows 8 prior open-market buys with an average 90-day return of -30.8% and a 0% win rate at the 90-day mark, indicating consistent poor timing on buy decisions. At ANIX specifically, his 5 prior trades (all buys) show mixed early outcomes: two June trades posted modest positive 30-day returns (+3.4% and +2.6%), but a third posted a loss (-5.6%), and the most recent two buys on July 25–26 remain too recent to measure. The company is unprofitable with annual revenue declining 59.0%, though the stock has rallied 49.3% in the past 30 days, suggesting recent market recovery rather than a fundamental inflection.

Director Lewis H Titterton Jr bought 8,496 shares at blended $3.01 (2 txns, $25.6K); stock up 30-day, down 39.2% from 52-week high; revenue collapsed -59% YoY, net loss $-3.1M.

Director Titterton made 2 separate purchases totaling 8,496 shares for $25,567.76 over two trading days (July 25–26, 2024) at prices near current levels ($3.01 blended vs. $3.05 current). His holdings increased by 1.0% post-transaction to 869,108 shares, a meaningful but incremental position accumulation. The purchase context is challenging: Anixa is unprofitable with annual revenue declining 59.0% year-over-year and a quarterly revenue base of only $210,000.00, yet the stock has rebounded 38.0% over the past 30 days after dropping 39.2% from its 52-week high. His cross-ticker trading track record shows 0% 90-day win rate across 6 prior buys with an average 90-day return of -30.8%, and his 5 prior same-ticker purchases at ANIX (June 2024) have not yet shown measurable 90-day outcomes but display mixed near-term returns (-9.6% to +3.4% at 30 days). The transaction occurs in a high-volatility, unprofitable biotech with deteriorating fundamentals, and the insider's historical timing record offers no confidence in the trade's forward-looking merit.